Zhonghua yi xue za zhi最新文献

{"title":"[Chinese clinical practice guidelines for transarterial interventions of hepatocellular carcinoma (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20260211-00457","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20260211-00457","url":null,"abstract":"<p><p>Transarterial interventions (TAI) for hepatocellular carcinoma (HCC) include transarterial chemoembolization (TACE), transarterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC), and selective internal radiation therapy (SIRT). TACE remains the first-line treatment for unresectable HCC. Chinese College of Interventionalists (CCI) previously issued and updated the Chinese Clinical Practice Guidelines of TACE for HCC in 2018, 2021, and 2023, which have played a pivotal role in standardizing TACE procedures in China. In recent years, the application of HAIC and SIRT has become increasingly widespread and standardized in China. With the continuous advancement of TAI techniques, the evolution of therapeutic concepts, and the emergence of high-level evidence, CCI has comprehensively revised and expanded its previous guidelines. The updated Chinese clinical practice guidelines for transarterial interventions of hepatocellular carcinoma (2026 edition) now formally incorporates TACE, HAIC, and SIRT as standard treatment modalities. With the aims to further standardize the use of TAI in the management of HCC, this guideline is developed based on the most current evidence-based medical research, integrates China-specific clinical practices, and incorporates the latest advancements in TAI for HCC. It elaborates on clinical diagnostic criteria and staging, patient indications and contraindications, operational procedures and requirements, perioperative management, common complications management, follow-up and efficacy evaluation, combination therapy, quality control, as well as hot topics and prospects.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 ","pages":"1998-2021"},"PeriodicalIF":0.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma].","authors":"R J Ma, P Zhou, Y B Liu, J H Zhuo, L F Wang, S Li, W Y Lu, X H Pei, S Q Zuo, H Xu, L Jiang, X L Chen, X L Yuan, Z M Zhu","doi":"10.3760/cma.j.cn112137-20260210-00448","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20260210-00448","url":null,"abstract":"<p><p>To analyze the clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue (MALT) lymphoma transformed into diffuse large B-cell lymphoma (DLBCL). A retrospective analysis was performed on patients diagnosed with MALT lymphoma at Henan Provincial People's Hospital from January 2016 to December 2025. According to whether DLBCL transformation occurred, the patients were divided into the transformed group (MALT lymphoma patients who developed DLBCL transformation) and the non-transformed group. The patients were followed up until December 30, 2025, and the clinical and genetic characteristics were compared between the two groups. A total of 175 patients were included, including 13 patients in the transformation group, 4 males and 9 females, aged (58±18) years; and 162 pattients in the non-transformed group, 73 males and 89 females, aged (57±12) years.The incidence of B symptoms in the transformed group [46.2% (6/13) vs 16.7% (27/162), <i>P</i>=0.018], the proportion with a MALT-international prognostic index (IPI) score≥2 point [69.2% (9/13) vs 17.3% (28/162), <i>P</i><0.001], and lactate dehydrogenase (LDH) levels [227 (194, 262) vs 173 (146, 196) U/L, <i>P</i><0.001] were all higher than those in the non-transformed group. The mutation rate of gene in the transformed group [84.6% (11/13) vs 45.7% (74/162), <i>P</i>=0.007] and the mutation rate of ≥2 genes [69.2% (9/13) vs 17.3% (28/162), <i>P</i><0.001] were both higher than those in the non-transformed group. The mutation rates of the NOTCH1 gene [23.1% (3/13) vs 3.7% (6/162), <i>P</i>=0.021], the SOCS1 gene [15.4% (2/13) vs 0, <i>P</i>=0.005], and the KRAS gene [15.4% (2/13) vs 0, <i>P</i>=0.005] were all higher in the transformed group than those in the non-transformed group. Patients with MALT lymphoma who transformed to DLBCL are often accompanied by B symptoms, a higher MALT-IPI score, elevated LDH and multiple gene mutations, and the mutation frequencies of NOTCH1, SOCS1, and KRAS are higher.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 ","pages":"2159-2163"},"PeriodicalIF":0.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical practice guideline for integrated PET/MRI in Parkinson's disease (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20251222-03386","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251222-03386","url":null,"abstract":"<p><p>To advance the precise diagnosis and treatment of Parkinson's disease (PD) and related movement disorders, standardize the clinical application of integrated PET/MRI, enhance diagnostic efficacy, and optimize patient management, the <i>Clinical Practice Guideline for Integrated PET/MRI in Parkinson's Disease (2026 Edition)</i> was developed jointly by multiple expert groups. This initiative was led by the Chinese Society of Medical Imaging Technology, the Radiological Society of Chinese Medical Association, the Chinese Society of Nuclear Medicine, the Beijing Society of Nuclear Medicine, and the Beijing Society of Radiology, in collaboration with a multidisciplinary panel of experts from Nuclear Medicine, Radiology, Neurology, and Functional Neurosurgery, following several rounds of consensus meetings. Compared to previous consensus statements or technical specifications, the key updates of this guideline include: in the clinical application pathway, it clarifies the advantages and appropriate scenarios for utilizing integrated PET/MRI over single-modality imaging when the clinical diagnosis of PD is uncertain; it emphasizes the value of simultaneous acquisition and fusion analysis in assessing both the function of the nigrostriatal dopaminergic pathway (e.g., via PET tracers) and structural alterations (e.g., via MRI neuromelanin imaging, diffusion tensor imaging, etc.). With the development and validation of novel tracers, the guideline provides a hierarchical recommendation for the differential diagnosis between PD and atypical parkinsonian syndromes (such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration), based on multimodal imaging biomarkers. Based on the premise of the accessibility of current integrated PET/MRI equipment and tracers in China, and grounded in the latest international and domestic evidence-based research, this guideline is meticulously aligned with the realities of Chinese clinical practice. It systematically delineates the technical specifications, clinical indications, and image interpretation criteria for the use of integrated PET/MRI in the diagnosis, differential diagnosis, disease severity assessment, and therapeutic decision support for PD. The aim is to provide systematic and practical evidence-based guidance for clinicians and imaging specialists involved in the care of patients with Parkinson's disease.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1541-1554"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Arachidonic acid metabolic characteristics of allergic bronchopulmonary aspergillosis and their value in differential diagnosis].","authors":"Q Wang, Z Y Liu, M T Liu, J Li, P Y Zheng, B Q Sun","doi":"10.3760/cma.j.cn112137-20251127-03103","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251127-03103","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the characteristics of 14 arachidonic acid (AA) metabolites in the serum of patients with allergic bronchopulmonary aspergillosis (ABPA), screen for differential metabolic biomarkers that can distinguish it from severe allergic asthma (SA), and construct a diagnostic model. &lt;b&gt;Methods:&lt;/b&gt; A cross-sectional study was conducted. A total of 19 patients with ABPA, 19 patients with SA, and 19 healthy controls (HC) from the First Affiliated Hospital of Guangzhou Medical University between December 2024 and July 2025 were enrolled as the training set. Additionally, a validation set consisting of 12 SA patients and 12 ABPA patients was recruited from the same center between September to December 2025. Peripheral blood cell counts and immunological and biochemical parameters were measured in all participants. Absolute quantification of 14 AA metabolites in serum was performed using ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) based on 5-(diisopropylamino) pentylamine derivative. Differences among groups were compared to identify significantly altered metabolites. In the training set, a combined clinical and metabolic indicator model was constructed using binary logistic regression. The diagnostic performance, calibration and clinical utility of the model were evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis, respectively. The model was further validated in the validation set. &lt;b&gt;Results:&lt;/b&gt; A total of 19 patients in the ABPA group were enrolled, aged 45 (33, 60) years, with 12 males; 19 patients in the SA group were aged 39 (29, 47) years, with 11 males; and 19 subjects in the HC group were aged 43 (34, 52) years, with 11 males. Compared with the SA group, patients with ABPA exhibited significantly higher levels of total IgE [1 578.00 (1 346.00, 2 538.00) U/ml vs 599.30 (382.20, 1 462.00) U/ml] and &lt;i&gt;Aspergillus fumigatus&lt;/i&gt;-specific IgE (&lt;i&gt;Af&lt;/i&gt;.sIgE) [4.93 (0.95, 8.41) kUA/L vs 0.27 (0.13, 2.17) kUA/L] (both &lt;i&gt;P&lt;/i&gt;&lt;0.05). Serum levels of arachidonic acid (AA), prostaglandin D&lt;sub&gt;2&lt;/sub&gt; (PGD&lt;sub&gt;2&lt;/sub&gt;), leukotriene B&lt;sub&gt;4&lt;/sub&gt; (LTB&lt;sub&gt;4&lt;/sub&gt;), 5-hydroxyeicosatetraenoic acid (HETE), 12-HETE, and 15-HETE were significantly higher in the ABPA group than in the HC group (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). Moreover, PGD&lt;sub&gt;2&lt;/sub&gt; [1.80 (0.82, 2.13) μg/L vs 0.63 (0.37, 1.15) μg/L] and 15-HETE levels [16.39 (11.15, 20.41) μg/L vs 9.31 (6.57, 10.86) μg/L] were significantly elevated in the ABPA group compared with the SA group. A four-indicator combined diagnostic model incorporating total IgE, &lt;i&gt;Af&lt;/i&gt;.sIgE, PGD&lt;sub&gt;2&lt;/sub&gt;, and 15-HETE was constructed. In the training set, the area under the curve (AUC) of the four-indicator combined model was 0.96 (95%&lt;i&gt;CI&lt;/i&gt;: 0.92-1.00), with a sensitivity of 0.93 and specificity of 0.95. In the validation set, the AUC was 0.91 (95%&lt;i&gt;CI&lt;/i&gt;: 0.81-1.00), with a sensitivity of 0.92 ","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1590-1596"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical practice guidelines for perioperative monitoring in elderly patients (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20251216-03320","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251216-03320","url":null,"abstract":"<p><p>Standardizing perioperative monitoring practices for elderly patients hold significant importance for systematic surgical risk management, optimizing healthcare resource allocation, and implementing the \"Healthy Aging\" strategy. Accordingly, the Geriatric Anesthesia and Perioperative Management Group of the Chinese Society of Anesthesiology, in collaboration with the National Alliance of Geriatric Anesthesia has developed the \"Clinical practice guidelines for perioperative monitoring in elderly patients (2026 edition)\" based on China's clinical realities and available evidence. The guideline covers core perioperative monitoring domains, including basic vital signs and cerebral, cardiac, pulmonary, coagulation, renal, and hepatic functions, resulting in 26 recommendations. It aims to provide standardized perioperative monitoring guidance for elderly surgical patients, transforming advanced age as an independent risk factor into quantifiable and intervenable clinical pathways.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1555-1577"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of house dust mite subcutaneous immunotherapy on plasma protein profiles in children with asthma].","authors":"J Y Li, W X Shen, L N Xu, Y F Wang, J Zhou, Q Y Yang, D Z Li, G G Zhang, J T Xue, C L Hao","doi":"10.3760/cma.j.cn112137-20251130-03128","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251130-03128","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; Preliminary analysis of dynamic expression characteristics of plasma proteins in children with allergic asthma during subcutaneous immunotherapy (SCIT) with dust mite allergens based on multi-time-point proteomics technology. &lt;b&gt;Methods:&lt;/b&gt; A cross-sectional study was conducted, enrolling 84 children with allergic asthma primarily sensitized to house dust mites (HDM) who visited the Children's Hospital of Soochow University between November 2024 and May 2025. Participants were categorized into five groups based on the duration of SCIT: 0M, 3M, 6M, 12M, and 24M. To detect the levels of specific immunoglobulin E (sIgE) and specific immunoglobulin G4 (sIgG4) against dust mite components (Der p1, Der f1, Der p2, Der f2, Der p5, Der p7, Der p10, Der p21, Der p23). Five subjects were randomly selected from each group using simple random sampling, and an additional 5 healthy children (HC) were included as the control group for plasma proteomic analysis. The temporal expression patterns of differentially expressed proteins were clustered via the Mfuzz algorithm and subjected to functional annotation. &lt;b&gt;Results:&lt;/b&gt; A total of 84 children were enrolled, with a mean age of (10.12±2.15) years, including 57 males and 27 females. Statistically significant differences were observed in Der p1-, Der f1-, Der p2-, and Der f2-specific IgG4 levels among the five groups (all P&lt;0.05). The 24M group exhibited significantly higher levels of Der p1-, Der f1-, Der p2-, and Der f2-specific IgG4 compared with the 0M group [Der p1: 695.20 (57.85, 1 894.60) vs 44.35 (32.10, 51.10); Der f1: 70.15 (51.35, 1 141.03) vs 46.65 (35.30, 63.68); Der p2: 3 440.20 (892.20, 4 183.00) vs 66.85 (43.08, 189.98); Der f2: 2 015.50 (704.60, 2 523.10) vs 69.10 (45.80, 159.35), all &lt;i&gt;P&lt;/i&gt;&lt;0.05]. Enrichment analysis of differentially expressed proteins in each group using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database showed that: compared with the healthy control group, the 0M group exhibited upregulation of cholesterol metabolism and complement/coagulation cascades, and downregulation of cornified envelope formation and ECM-receptor interaction pathways. compared with the 0M group, the 3M group showed upregulation of ECM-receptor interaction and focal adhesion and downregulation of fatty acid metabolism. The 6M group showed upregulation of cell adhesion molecules and downregulation of cholesterol metabolism; the 12M and 24M groups showed upregulation of TGF-β and PI3K-Akt pathways. Fuzzy C-means clustering analysis revealed that proteins highly expressed in the 6M group were enriched in glutathione metabolism, while those in the 24M group were significantly enriched in B cell-mediated immune responses. Six potential regulatory proteins (ARPC3, LPL, ILF3, FARSB, USP14, and SLIT2) were initially identified. Furthermore, Spearman correlation analysis revealed that ARPC3 was significantly negatively correlated with the levels of Der f2-sIgE, Der p2","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1605-1614"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical practice guideline for integrated PET/MRI in Alzheimer's disease (2026 edition)].","authors":"","doi":"10.3760/cma.j.cn112137-20251222-03384","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251222-03384","url":null,"abstract":"<p><p>To further standardize the clinical use of integrated PET/MRI brain imaging for Alzheimer's disease (AD) in China, improve early identification and precision diagnosis and management of AD, promote standardized care, and provide evidence-based and consensus recommendations for clinicians and imaging professionals, experts in nuclear medicine, radiology, neurology, and related fields developed this guideline through a consensus process informed by the available research evidence and clinical practice. AD is one of the most common forms of dementia in older adults, with an insidious course; early diagnosis and timely intervention are crucial to improving patient outcomes. Integrated PET/MRI enables the simultaneous, one-stop acquisition of multidimensional information-including cerebral amyloid burden, brain metabolism, and high-resolution anatomical detail-and can be used for early diagnosis, clinical staging, assessment of disease progression, and clinical trial research, making it an important imaging tool for precision care in AD. As integrated PET/MRI systems become increasingly available in China, broader clinical implementation continues to face challenges, including appropriate patient selection and indications, standardization of scanning workflows, image quality control, consistency in image interpretation, and reporting standards. With a focus on clinical feasibility, this guideline provides recommendations across key domains-indications, examination and quality-control procedures, image interpretation, and standardized reporting-with the aim of promoting the standardized use of integrated PET/MRI in AD care and advancing research and translation of relevant imaging biomarkers.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1527-1540"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Multicenter component-resolved study of inhalant allergen sensitization and cross-reactivity in airway allergic patients].","authors":"L Liu, J L Zhang, Q Y Chen, B Chang, W T Luo, B Q Sun","doi":"10.3760/cma.j.cn112137-20251130-03141","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251130-03141","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the molecular sensitization profiles of inhalant allergens in Chinese patients with airway allergies using component-resolved diagnosis (CRD) and to analyze their distributional characteristics. <b>Methods:</b> In this cross-sectional study, allergen component testing data were collected from 225 patients diagnosed with allergic rhinitis (AR) and/or allergic asthma (AS) across 20 medical centers in 13 provinces (Northern, Southern, and Northwestern China) between October 2019 and January 2023. Specific immunoglobulin E (sIgE) levels for 132 components were analyzed. Sensitization differences were compared across clinical phenotypes, age stratifications, and geographical regions. Spearman correlation analysis was employed to evaluate molecular cross-reactivity. <b>Results:</b> Among the 225 patients [mean age: (19.40±17.53) years; 119 males, 106 females], children aged 0-6 and 7-14 years accounted for 58.67% (132/225). Regarding overall distribution, the predominant sensitizing components were <i>Artemisia vulgaris</i> (Art v 1, 43.11%), dust mites (Der p 2, 39.11%; Der f 2, 38.22%), and <i>Phleum pratense</i> (Phl p 12, 39.11%). Phenotypically, while the AR combined with AS group exhibited the broadest polysensitization, the AR only group was distinct for its significantly higher sensitization to cat (Fel d 1, 68.42%) and dog (Can f 1,36.84%) dander (both <i>P</i><0.05). Conversely, pollen sensitization was relatively lower in the AS only group. Regarding age, children (0-6 and 7-14 years) showed early sensitization to pan-allergens (e.g., Phl p 12, Bet v 2) and fungi (Alt a 1), whereas dust mite components (Der f 2, Der p 2, Der p 23) showed lower prevalence in the 0-6 group (23.19%, 23.19%, and 10.14%, respectively). Regional analysis highlighted a \"Northern Pollen vs Southern Mite\" dichotomy: weeds (Artemisia>60%) and tree pollen dominated the Northwest and North, whereas mites (>60%) and cockroaches dominated the South (<i>P</i><0.001). Furthermore, extensive molecular cross-reactivity was confirmed within the Serum Albumin and Profilin families. <b>Conclusions:</b> Significant heterogeneity exists in sensitization profiles across phenotypes, ages, and regions. Mugwort and mites are core allergens. CRD facilitates the identification of cross-reactivity and guides precise, regionalized management.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1615-1623"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Precision medicine in the diagnosis of allergic airway diseases: current applications and future directions].","authors":"Z Y Liu, Q Wang, B Q Sun","doi":"10.3760/cma.j.cn112137-20251129-03122","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251129-03122","url":null,"abstract":"<p><p>The rapid advancement of precision medicine is shifting the clinical diagnosis of allergic airway diseases away from traditional models that rely solely on symptoms and phenotypes, and toward individualized, precision-based diagnoses that are molecularly driven. This review describes the role of established biomarker systems, such as eosinophil count, fractional exhaled nitric oxide, and specific immunoglobulin E, in inflammatory endotyping and targeted therapy. Furthermore, the integration of multi-omics technologies and artificial intelligence algorithms facilitates the elucidation of disease heterogeneity and molecular mechanisms, thereby advancing precision stratification. The proposal of this article is an integrated precision diagnostic framework combining multi-dimensional data integration, dynamic monitoring, and intelligent analysis. By establishing a systematic biomarker evaluation pathway, this framework aims to promote the application of real-time monitoring technologies and AI-assisted decision-making, thereby providing a reference for the optimization and evolution of next-generation precision diagnostic systems.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1521-1526"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy of pre-pollen season medication for seasonal allergic rhinitis and asthma in children from Hohhot].","authors":"X H Zhang, W Wang, L T Y Wulan, W Wang, H Y Na, H J Cai, H T Wang, J J Zhang","doi":"10.3760/cma.j.cn112137-20251202-03161","DOIUrl":"https://doi.org/10.3760/cma.j.cn112137-20251202-03161","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the efficacy and optimal timing of prophylactic medication before pollen season for children with seasonal allergic rhinitis (AR) and allergic asthma (AA) in Hohhot. <b>Methods:</b> A prospective, self-controlled study was conducted. Children aged 4-14 years who were diagnosed with AR or AR+AA in Hohhot First Hospital from January to August 2024 were enrolled, with the same patients undergoing self-medication in 2024 pollen season as the controls. Before 2025 pollen season, children were stratified into eight groups based on disease type (AR/AR+AA), severity of disease (mild/moderate-severe), and onset season (spring/autumn). For each group, prophylactic medication was initiated at 5, 10, 15, and 20 days before the season, respectively. Symptom onset time, symptomatic days, visual analogue scale (VAS) score, total medication score (TMS), and childhood asthma control test (C-ACT) score were compared between the two groups. <b>Results:</b> A total of 312 children were included in the study, consisting of 183 males (58.7%) and 129 females (41.3%), with a mean age of (8.6±3.0) years. After initiating medication 5, 10, and 15 days before the season for mild spring, moderate-severe spring and mild autumn, and moderate-severe autumn AR cases, respectively, children experienced significantly shorter symptomatic periods and lower VAS scores than those in the self-medication group (all <i>P</i><0.01). For children with AR+AA, clinical indicators (symptomatic days, VAS score, and C-ACT score) were significantly improved after initiating medication 15 days in advance for mild spring cases and 20 days in advance for other subgroups (all <i>P</i><0.01). The proportions of pre-season symptoms in the prophylactic medication groups were lower, and TMS scores were higher (all <i>P</i><0.01). <b>Conclusion:</b> Stratified prophylactic medication based on disease severity before the pollen season can delay symptom onset, alleviate symptom severity, and shorten the duration of symptoms in children with AR and AA.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"106 16","pages":"1597-1604"},"PeriodicalIF":0.0,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}